Skip to main content

Advertisement

Table 3 Peri-procedural drug therapy

From: The outcomes of patients with very small coronary artery disease treated with thin strut cobalt chromium bare metal stents: an observational study

Drug type Drug All patients Vessel diameters ≤2.50 mm Vessel diameters >2.5 mm p value small versus large vessel diameters
Antiplatelet therapy (APT) Aspirin 783 (100 %) 205 (100.0 %) 578 (100.0 %) 0.009
Clopidogrel 663 (84.7 %) 164 (80.0 %) 499 (86.3 %)
Prasugrel 78 (10.0 %) 23 (11.2 %) 55 (9.5 %)
Ticagrelor 30 (3.8 %) 16 (7.8 %) 14 (2.4 %)
Ticlopidine 2 (0.3 %) 0 (0.0 %) 2 (0.3 %)
GP IIb/IIIa inhibitors 10 (1.3 %) 2 (1.0 %) 8 (1.4 %)
Oral anti-coagulation None 694 (88.6 %) 188 (91.7 %) 506 (87.5 %) 0.106
Vitamin K antagonist (VKA) 74 (9.5 %) 12 (5.9 %) 62 (10.7 %)
New oral anticoagulation (NOAC) rivaroxaban 15 (1.9 %) 5 (2.4 %) 10 (1.7 %)
Triple Therapy (OAC + DAPT) OAC + Aspirin + Clopidogrel 70 (8.9 %) 14 (6.8 %) 56 (9.7 %) 0.451
OAC + Aspirin + Prasugrel 2 (0.3 %) 0 (0.0 %) 2 (0.3 %)
OAC + Aspirin + Ticagrelor 1 (0.1 %) 0 (0.0 %) 1 (0.2 %)
  1. OAC oral anti-coagulation